Full-Time
Business Operations Manager
Scientific Department
Posted on 10/31/2025
Celerion
1,001-5,000 employees
Global CRO for early-phase development
No salary listed
Lincoln, NE, USA
Hybrid
 Operations & Logistics (1) |
|---|
 Business & Strategy (1) |
|---|
- Bachelor’s degree in Business, Life Sciences or related field required.
- Requires high-level skills in the areas of strategic thinking, organization, multi-tasking, relationship-building, communication, judgment, problem-solving, persuading and negotiating.
- Minimum 2 years industry experience, or equivalent, required.
- Define and clarify DMB project scope with Global Project Managers (GPM), clients, and internal teams
- Review and align DMB fees with project scope; communicate expectations to delivery teams
- Coordinate with GPMs and functional managers to assign and prioritize work based on project and team needs
- Coach and support DMB team members to ensure successful project outcomes
- Manage multiple DMB projects, ensuring timelines and deliverables are met
- Lead regular team meetings to maintain engagement and alignment with client expectations
- Monitor project progress, proactively address risks, and ensure adherence to timelines and contracts
- Drive monthly revenue by prioritizing project work and maintaining performance metrics
- Build strong client relationships to support repeat business
- Identify and implement process improvements to enhance team efficiency
- Maintain accurate project data and generate reports for month-end summaries
- Scientific background related to understanding general research process preferred
- 3 years project team experience preferred
- Business management experience desired
Celerion is a global contract research organization focused on early-phase drug development. It supports pharmaceutical and biotech clients with trial design, feasibility, project management, clinical and medical monitoring, bioanalytical sciences, and regulatory affairs, all conducted under contract. Its work hinges on metabolite profiling using high-resolution mass spectrometry to inform development decisions. With 40+ years of experience and a global, integrated service network, Celerion aims to help clients bring safe, effective treatments to patients faster by delivering rigorous, timely research.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Lincoln, Nebraska
Founded
2010
Simplify's Take
What believers are saying
- THL Partners' acquisition post-H.I.G. 2022 investments accelerates Celerion's global expansion.
- Labnotes software enhanced May 6, 2025, streamlines bioanalytical data for faster sponsor decisions.
- GLP/GCP molecular testing expansion supports surging cell/gene therapy demand in Lincoln/Zürich.
What critics are saying
- THL Partners cuts costs post-acquisition, eroding Celerion employee retention within 12-24 months.
- WuXi AppTec Belfast expansion captures EU clients with 40% lower HRMS pricing in 6-12 months.
- FDA AI audits expose Labnotes flaws, holding 30% bioanalytical submissions for 6 months.
What makes Celerion unique
- Celerion pioneered VCT biometric fingerprint technology, verifying 50,000 participants over five years.
- Celerion earned first US CRO full AAHRPP accreditation, exceeding federal participant protections.
- Celerion leads early-phase CROs with 650+ beds across North America, Europe, and Asia.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 4%LINCOLN, Neb.; May 6, 2025 (Business Wire) – Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors. The latest system enhancements streamline laboratory documentation and improve operational efficiency for users. The updated platform also offers advanced tools for handling and organizing large datasets, ensuring faster processing of reports and optimized database queries
Celerion launches enhanced version of labnotes bioanalytical data Management software.
Celerion was recognized as a CRO Leader in the quality, capabilities and reliability categories across two groups of respondents (small pharma and combined big and small pharma).
Celerion announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory.Post this
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory. In her new role, Goodman will oversee the strategic direction and operational performance of the Lincoln bioanalytical laboratory, leveraging her extensive experience in pharmaceutical research and development to drive innovation and design and execute customized bioanalysis for clients’ needs. She will be responsible for delivering on Celerion’s bioanalytical promise of industry-leading science, stringent compliance, and speed of delivery. With over 29 years of experience in the pharmaceutical industry, Goodman brings a wealth of knowledge in regulated GxP and discovery bioanalysis for both in-house and outsourced activities. Prior to joining Celerion, she held positions of increasing responsibility at AstraZeneca, MedImmune, and GlaxoSmithKline. Additionally, Goodman is a recognized thought leader, having recently served as a member of the Expert Working Group (EWG) for ICH M10 Bioanalytical Guidance Development and is active in numerous non-profit industry consortia such as EBF, AAPS, and DMDG